Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis

BACKGROUND: Oral miltefosine has been shown to be non-inferior to first-line, injectable meglumine antimoniate (MA) for the treatment of cutaneous leishmaniasis (CL) in children. Miltefosine may be administered via in-home caregiver Directly Observed Therapy (cDOT), while patients must travel to cli...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS Negl Trop Dis
Autors principals: Berger, Brandon A., Cossio, Alexandra, Saravia, Nancy Gore, Castro, Maria del Mar, Prada, Sergio, Bartlett, Allison H., Pho, Mai T.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5404883/
https://ncbi.nlm.nih.gov/pubmed/28384261
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pntd.0005459
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars